<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382263</url>
  </required_header>
  <id_info>
    <org_study_id>PHR-2012-01</org_study_id>
    <nct_id>NCT02382263</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer</brief_title>
  <acronym>FRAGANCE</acronym>
  <official_title>Phase I/II Study to Assess the Efficacy and Safety of Nab-paclitaxel in Combination With Gemcitabine for the Treatment of Fragile Patients With Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PH Research, S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PH Research, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the list of cancer mortality by type of cancer pancreatic cancer ranks 4th in USA and the
      6th in Europe. The estimated figures for 2010 in the USA were 42,000 new cases and 36,000
      deaths from pancreatic cancer. The survival rate at 5 years after diagnosis is 4.6% in the
      USA. In Europe the figures are similar, with survival at 1, 3 and 5 years of 16%, 6% and 4%,
      respectively. Most patients are diagnosed in advanced stages that are no longer operable, so
      that treatment goals are often the prolongation of survival and palliation of symptoms.

      The aim of the study is to explore whether the new combination nab-paclitaxel plus
      gemcitabine is a therapeutic advance for this fragile population for which it is assumed that
      some modifications in dose and schedule of administration may be necessary in patients with
      good performance status. It is ultimately to find out the clinical benefit of this
      combination, but first making sure that dose and schedule of the combination are tolerable
      for these fragile patients.

      For this, the investigators have chosen a design that includes two stages: the first step
      aimed at choosing the safest treatment regimen for these patients among a group of treatment
      regimens used in other clinical trials. The second step will evaluate the effectiveness of
      the two regimens with the better results in the previous step.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PHASE I: To select the schemes with the best therapeutic indexes of the combination of gemcitabine and nab-paclitaxel in fragile patients with advanced pancreatic cancer.</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Phase I: Therapeutic index. Criteria: Early mortality all causes at 30 and 60 days, Adverse Events grade 3 and 4, treatment discontinuation due to toxicity and relative dose intensity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PHASE II: Evaluate the effectiveness of two selected schemes of gemcitabine and nab-paclitaxel, vs. gemcitabine alone. (Six months overall survival)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Six months overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: evaluate safety profile of gemcitabine and nab-paclitaxel schemes. (Number of events per patient according to NCI-CTC-AE criteria)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of events per patient according to NCI-CTC-AE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: evaluate objective response rate. (Response rate will be evaluated according RECIST criteria)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Response rate will be evaluated according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: progression free survival (Time from randomization to disease progression according RECIST criteria)</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Time from randomization to disease progression according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: objective response rate (Response rate will be evaluated according RECIST criteria)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Response rate will be evaluated according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: to explore changes induced by treatment on tumor Marker CA19.9</measure>
    <time_frame>Up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: change in FAP and Cav-1 tumor markers as an inidicatior of treatment efficacy</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4</intervention_name>
    <description>Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4</intervention_name>
    <description>Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4</intervention_name>
    <description>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4</intervention_name>
    <description>Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are 18 years or older;

          -  Patients with histological or, if not possible, cytologic confirmed adenocarcinoma of
             the pancreas.

          -  Patients with metastatic pancreatic cancer;

          -  Patient with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2

          -  Adequate hematopoietic, hepatic and renal function:

          -  Neutrophil count &gt;= 1.5 x 10*9/L;

          -  Platelet count &gt;= 100 x 10*9/L;

          -  Bilirubin &lt;= 1.5 x ULN;

          -  AST and/or ALT &lt;= 2.5 x ULN;

          -  Serum creatinine &lt;= 1.5 x ULN.

          -  Investigators must ensure that patients enrolled in the study will be available for
             all study procedures, including tumor biopsy, chemotherapy treatment, and follow up.

          -  Investigators must ensure that patients have the ability to understand the
             requirements of the study and provide signed informed consent.

          -  Women of childbearing potential and men who wish to participate in the study must
             agree to use adequate contraception since the signing of informed consent until at
             least 3 months after stopping the study medication;

          -  Signed Informed Consent.

        Exclusion Criteria:

          -  Active or uncontrolled infections or serious illnesses or medical conditions that
             could interfere with patient eligibility for treatment;

          -  History of any psychiatric condition that might impair patient?s ability to understand
             or to comply with the requirements of the study or to provide informed consent;

          -  Concurrent anticancer therapy;

          -  Pregnant or breast-feeding women (documented methods of birth control are required in
             those with reproductive potential);

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study drugs;

          -  History of life threatening reaction to gemcitabine or abraxane;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) &lt;=1.

          -  Previous treatment with chemotherapy or chemoradiotherapy for advanced pancreatic
             cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Madrid Sanchinarro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Rivera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO MARQUÉS DE VELDECILLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Macarulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Guillén, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEXO HOSPITALARIO UNIVERSITARIO DE SANTIAGO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Pazo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO MIGUEL SERVET</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Valladares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEXO HOSPITALARIO UNIVERSITARIO A CORUÑA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto P Díaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inmaculada Alés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL DE MÁLAGA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquina Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL VIRGEN DE LAS NIEVES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adelaida La Casta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO DONOSTIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rut Vera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrés Muñoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO GREGORIO MARAÑÓN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José I Martín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DIAZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Sastre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Cosuña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced pancreatic cancer</keyword>
  <keyword>Fragile</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

